PT - JOURNAL ARTICLE AU - Kevin Zhang AU - Avika Misra AU - Patrick J. Kim AU - Seyed M. Moghadas AU - Joanne M. Langley AU - Marek Smieja TI - Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario AID - 10.1101/2020.11.27.20240036 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.27.20240036 4099 - http://medrxiv.org/content/early/2020/12/24/2020.11.27.20240036.short 4100 - http://medrxiv.org/content/early/2020/12/24/2020.11.27.20240036.full AB - Background Public health measures, such as social distancing and closure of schools and non-essential services, were rapidly implemented in Canada to interrupt the spread of the novel coronavirus disease 2019 (COVID-19).Objective We sought to investigate the impact of mitigation measures during the spring wave of COVID-19 on the incidence of other laboratory-confirmed respiratory viruses in Hamilton, Ontario.Methods All nasopharyngeal swab specimens (n = 57,503) submitted for routine respiratory virus testing at a regional laboratory serving all acute-care hospitals in Hamilton, Ontario between January 2010 and June 2020 were reviewed. Testing for influenza A/B, respiratory syncytial virus, human metapneumovirus, parainfluenza I–III, adenovirus and rhinovirus/enterovirus was done routinely using a laboratory-developed polymerase chain reaction multiplex respiratory viral panel. A Bayesian linear regression model was used to determine the trend of positivity rates of all influenza samples for the first 26 weeks of each year from 2010 to 2019. The mean positivity rate of Bayesian inference was compared with the weekly reported positivity rate of influenza samples in 2020.Results The positivity rate of influenza in 2020 diminished sharply following the population-wide implementation of COVID-19 interventions. Weeks 12-26 reported 0% positivity for influenza, with the exception of 0.1% reported in week 13.Conclusions Public health measures implemented during the COVID-19 pandemic were associated with a reduced incidence of other respiratory viruses and should be considered to mitigate severe seasonal influenza and other respiratory virus pandemics.Competing Interest StatementJoanne Langley reports that Dalhousie University has received payment for the conduct of vaccine studies from Sanofi, Glaxo-SmithKline, Merck, Janssen, VBI and Pfizer. Dr. Langley holds the Canadian Institutes of Health Research-GlaxoSmithKline Chair in Pediatric Vaccinology. No other competing interests were declared.Funding StatementSeyed Moghadas: CIHR (OV4-170643), COVID-19 Rapid Research; Natural Sciences and Engineering Research Council of Canada; and Canadian Foundation for Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hamilton Integrated Research Ethics Board (Project: 07-2923). The study was categorized as minimal risk, defined as no potential for negative impact on the health and safety of the participant, and waiver of individual consent for participation was obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for the study are not publicly available due to the presence of personally identifiable information. Aggregate data, however, are presented in the manuscript within the Table, Figure, and Supplementary File and are available from the corresponding author on reasonable request.